Embecta (Nasdaq:EMBC) today posted fourth-quarter financial results that proved mixed compared to the consensus forecast on Wall Street.
Shares of EMBC remained unmoved at $14.64 apiece in pre-market trading today.
The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $26.4 million. That equals 45¢ per share on sales of $264 million for the three months ended Sept. 30, 2025.
Embecta recorded an 80.8% bottom-line gain on a sales decrease of 7.7%.
Adjusted to exclude one-time items, earnings per share came in at 50¢. That landed 4¢ ahead of expectations on Wall Street. Sales, however, came up shy of projections, as experts forecast $265.7 million.
The company said its recent strategic highlights include strengthening its core business, completing its brand transition in the U.S. and Canada. It now has the next phase underway globally, with plans to complete the transition internationally by the end of calendar year 2026.
Embecta — one of the largest diabetes tech companies in the world — continues to expand its product portfolio, progressing on its GLP-1 strategy and adding its pen needles to GLP-1 partner-managed regulatory submissions. It expects generic GLP-1 commercial launches in select countries potentially beginning next year.
Read more about Embecta and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
The company also reduced debt during the most recent quarter, paying down about $72.4 million under a term loan B facility. That brought its total 2025 debt reduction to about $184.5 million, exceeding its target of $110 million
Embecta expects adjusted EPS to range between $2.80 and $3.00 for the full year. It projects between $1.071 billion and $1.093 billion in sales.
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang maintained a “Buy” rating for Embecta on the results. They note that, while sales fell short of expectations, the company “handily beat all profit metrics.”
The analysts also said Embecta confirmed the $10 million sale of assets related to its discontinued insulin patch pump system. This will be reflected as a one-time gain in 2026, for which the analysts view overall guidance reflects a “cautious approach.”
“Overall, this was a solid quarter for [Embecta] as the company continues to execute on several initiatives,” the analysts wrote. “We also think that the guide has been set at a reasonable level that leaves room for upside.”
Commentary from Embecta CEO Devdatt (Dev) Kurdikar
In a meeting with analysts earlier this year, Embecta management noted considerations for potential market exits with existing manufacturing overhead and selling costs potentially providing hurdles. Embecta said it had near-term concerns about the Chinese market, the analysts said, with tariffs and geopolitical tensions leading to customers buying more local brands.
Those concerns likely impacted the company’s fourth-quarter results. The analysts also pointed out that the results included few surprises, given previous warnings on China.
“Our fourth quarter results were largely in line with our expectations, with revenue lower year over year due to several items we had previously anticipated, including the impact of advanced distributor ordering in the fourth quarter of fiscal year 2024 in advance of a potential U.S. port strike; the impact of advanced distributor ordering in the third quarter of fiscal year 2025 in advance of the U.S. July 4th holiday; and the continuing business dynamics in China,” said Kurdikar.
Kurdikar said the past year marked the completion of the first phase of the company’s strategic roadmap. With the second phase (seeding growth) now initiated, the company executed restructuring and accelerated debt reduction.
We remain committed to the initiatives announced at our 2025 Analyst and Investor Day, and in fiscal year 2026, we intend to maintain our global leadership position in our core product categories, execute on our new product programs, and generate strong adjusted operating margin and free cash flow,” Kurdikar said. “While the broader geopolitical and trade environment remains dynamic, we believe our global scale, resilient supply chain, and experienced teams position us well to build value for all stakeholders.”
